Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Xenetic Biosciences, Inc.

  • FRAMINGHAM, Massachusetts
  • Public · NASDAQ: XBIO
  • 2 employees
$7.1MMarket cap
$3.0MRevenue · FY2025
-$2.7MNet income
2Employees
XBIONASDAQ
2012IPO

About Xenetic Biosciences, Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$3.0M
Net income
-$2.7M
Total assets
$8.4M
Market cap
$7.1M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: XBIO

15-minute delayed · data by Polygon.io

Market cap
$7.1M
Open
Day range
Prev close
Volume
IPO date
May 16, 2012

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Xenetic Biosciences, Inc..

Write a review
Explore

Similar companies

Browse all →